1
Clinical evaluation of naltrexone treatment of
opiate-dependent individuals. Report of the National Research Council
Committee on Clinical Evaluation of Narcotic Antagonists.
Arch Gen Psychiatry
1978; 35: 335–40.
2
Minozzi, S, Amato, L, Vecchi, S, Davoli, M, Kirchmayer, U, Verster, A. Oral naltrexone maintenance treatment for opioid
dependence. Cochrane Database Syst Rev
2006; 1:
CD001333.
3
Sullivan, MA, Rothenberg, JL, Vosburg, SK, Church, SH, Feldman, SJ, Epstein, EM, et al. Predictors of retention in naltrexone
maintenance for opioid dependence: analysis of a stage I
trial. Am J Addict
2006; 15: 150–9.
4
Greenstein, RA, Arndt, IC, McLellan, AT, O'Brien, CP, Evans, B. Naltrexone: a clinical perspective.
J Clin Psychiatry
1984; 45: 25–8.
5
Bell, JR, Young, MR, Masterman, SC, Morris, A, Mattick, RP, Bammer, G. A pilot study of naltrexone-accelerated
detoxification in opioid dependence. Med J
Aust
1999; 171:
26–30.
6
Hulse, GK, Basso, MR. The association between naltrexone compliance and
daily supervision. Drug Alcohol Rev
2000; 19: 41–8.
7
Waal, H, Aamodt, O, Olsen, H. [Use of naltrexone in the treatment of young drug
addicts.]
Tidsskr Nor Laegeforen
2003; 123: 1662–4.
8
Comer, SD, Sullivan, MA, Hulse, GK. Sustained-release naltrexone: novel treatment for
opioid dependence. Expert Opin Investig
Drugs
2007; 16: 1285–94.
9
Comer, SD, Sullivan, MA, Yu, E, Rothenberg, JL, Kleber, HD, Kampman, K, et al. Injectable, sustained-release naltrexone for
the treatment of opioid dependence: a randomized, placebo-controlled
trial. Arch Gen Psychiatry
2006; 63: 210–8.
10
Lobmaier, P, Kornor, H, Kunoe, N, Bjorndal, A. Sustained-release naltrexone for opioid
dependence. Cochrane Database Syst Rev
2008; 2:
CD006140.
11
Brewer, C. Serum naltrexone and 6-beta-naltrexol levels from
naltrexone implants can block very large amounts of heroin: a report of
two cases. Addict Biol
2002; 7: 321–3.
12
Foster, J, Brewer, C, Steele, T. Naltrexone implants can completely prevent early
(1-month) relapse after opiate detoxification: a pilot study of two
cohorts totalling 101 patients with a note on naltrexone blood
levels. Addict Biol
2003; 8: 211–7.
13
Carreno, JE, Alvarez, CE, San Narciso, GL, Bascarán, MT, Díaz, M, Bobes, J, et al. Maintenance treatment with depot opioid
antagonists in subcutaneous implants: an alternative in the treatment of
opioid dependence. Addict Biol
2003; 8: 429–38.
14
Hulse, GK, Arnold-Reed, DE, O'Neil, G, Chan, CT, Hansson, R, O'Neil, P. Blood naltrexone and 6-beta-naltrexol levels
following naltrexone implant: comparing two naltrexone
implants. Addict Biol
2004; 9:
59–65.
15
Hulse, GK, Tait, RJ, Comer, SD, Sullivan, MA, Jacobs, IG, Arnold-Reed, D. Reducing hospital presentations for opioid overdose
in patients treated with sustained release naltrexone
implants. Drug Alcohol Depend
2005; 79: 351–7.
16
Ngo, HT, Arnold-Reed, DE, Hansson, RC, Tait, RJ, Hulse, GK. Blood naltrexone levels over time following
naltrexone implant. Prog Neuropsychopharmacol
Biol Psychiatry
2008; 32: 23–8.
17
Reece, AS. Psychosocial and treatment correlates of opiate free
success in a clinical review of a naltrexone implant
program. Subst Abuse Treat Prev Policy
2007; 2: 35.
18
Waal, H, Christophersen, AS, Frogopsahl, G, Olsen, LH, Morland, J. [Naltrexone implants – a pilot
project.]
Tidsskr Nor Laegeforen
2003; 123: 1660–1.
19
Olsen, L, Christophersen, AS, Frogopsahl, G, Waal, H, Morland, J. Plasma concentrations during naltrexone implant
treatment of opiate-dependent patients. Br J Clin
Pharmacol
2004; 58: 219–22.
20
Waal, H, Frogopsahl, G, Olsen, L, Christophersen, AS, Morland, J. Naltrexone implants – duration, tolerability and
clinical usefulness. A pilot study. Eur Addict
Res
2006; 12: 138–44.
21
Waal, H. Merits and problems in high-threshold methadone
maintenance treatment. Evaluation of medication-assisted rehabilitation
in Norway 1998–2004. Eur Addict Res
2007; 13:
66–73.
22
McLellan, AT, Kushner, H, Metzger, D, Peters, R, Smith, I, Grissom, G, et al. The Fifth Edition of the Addiction Severity
Index. J Subst Abuse Treat
1992; 9:
199–213.
23
Sobell, LC, Sobell, MB. Timeline follow-back: a technique for assessing
self-reported alcohol consumption. In Measuring
Alcohol Consumption: Psychosocial and Biochemical Methods (eds
Litten, RZ & Allen, JP): 41–72. Humana
Press, 1992.
24
American Psychiatric Association. Diagnostic and
Statistical Manual of Mental Disorders (4th edn) (DSM–IV).
APA, 1994.
25
Sheehan, DV, Lecrubier, Y. Mini-International Neuropsychiatric Interview
. University of
South Florida, 1998.
26
Kotkevi, A, Hargers, C. EUROPASI: European adaptation of a multidimensional
assessment instrument for drug and alcohol dependence.
Eur Addict Res
1995: 1: 208–10.
27
Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J. An inventory for measuring
depression. Arch Gen Psychiatry
1961; 4: 561–71.
28
Derogatis, LR, Lipman, RS, Rickels, K, Uhlenhuth, EH, Covi, L. et al. The Hopkins Symptom Checklist (HSCL): a
self-report symptom inventory. Behav Sci
1974; 19:
1–15.
29
Pavot, W, Diener, E, Suh, E. The Temporal Satisfaction With Life
Scale. J Pers Assess
1998; 70: 340–54.
30
Hegstad, S, Khiabani, H, Kristoffersen, L, Kunøe, N, Lobmaier, P, Christophersen, AS. Drug screening of hair by liquid
chromatography–tandem mass spectrometry. J Anal
Toxicol
2008; 32: 364–72.
31
Shearer, J, White, B, Gilmour, S, Wodak, AD, Dolan, KA. Hair analysis underestimates heroin use in
prisoners. Drug Alcohol Rev
2006; 25: 425–31.
32
Gossop, M, Stewart, D, Browne, N, Marsden, J. Factors associated with abstinence, lapse or relapse
to heroin use after residential treatment: protective effect of coping
responses. Addiction
2002; 97: 1259–67.
33
Garbutt, JC, Kranzler, HR, O'Malley, SS, Gastfriend, DR, Pettinati, HM, Silverman, BL, et al. Efficacy and tolerability of long-acting
injectable naltrexone for alcohol dependence: a randomized controlled
trial. JAMA
2005; 293: 1617–25.
34
Pettinati, HM, O'Brien, CP, Rabinowitz, AR, Wortman, SP, Oslin, DW, Kampman, KM, et al. The status of naltrexone in the treatment of
alcohol dependence: specific effects on heavy drinking.
J Clin Psychopharmacol
2006; 26: 610–25.
35
O'Malley, SS, Garbutt, JC, Gastfriend, DR, Dong, Q, Kranzler, HR. Efficacy of extended-release naltrexone in
alcohol-dependent patients who are abstinent before
treatment. J Clin Psychopharmacol
2007; 27: 507–12.
Nikolaj Kun�
22 October 2009
We are happy to clarify: Of the 667 patients, 265 opioid dependent patients entered inpatient treatment for induction onto agonist maintenance treatment and were therefore excluded. Also, patients who left their respective clinics prematurely were not eligible for participation (n=193). Eleven were excluded due to psychotic symptoms, 8 due to pregnancy, and 17 due to extreme ALT/AST values.
This left n=173 opioid dependent patients as satisfying inclusion criteria. However, the virtually complete novelty of naltrexone implant treatment in Norway at the time of recruitment probably means that these results are a poor basis upon which to base estimates of demand for this form of treatment.
The randomized trial period was followed by an implantation or re-implantation opportunity for all patients, meaning that the proportion of patients who entered inpatient treatment again at the end of the study to detoxify or stabilise is probably higher than future clinical samples.Reporting it as a result or as part of a figure could be regarded as misleading. ... More
Conflict of interest: None Declared
Write a replyBack to top
Kathleen I Kelly, Specialist Registrar Psychiatry
30 September 2009
The report by Kuone et al(1) of the first randomised controlled trialof naltrexone implants is of great interest.
The authors identify two inclusion criteria in their methodology:being an in-patient and being 18years or above. Exclusion criteria are given as psychosis,pregnancy and serious hepatic disease. Of 667 possible participants 480 are excluded. In the results,the term "ineligibility" is used to describe not completeing treatment,starting maintenance and transfer to other clinics. Could the authors clarify when these additional criteria were decided upon,and how many were excluded foreach reason? Given that all 667 patients were receiving "abstinence-orinated" in-patient treatment,it is notable that only a small proportion of patients were eligible for,or wanted such treatment.The characteristicsof the ineligible or refusal group could provide important information about which group of opiate dependent patients are likely to benefit from naltrexone.
Data on opiod use throughout the period of treatment would be of value. In the non-abstainers we would expect both groups to use in the first few days,but behavioural extinction to occur in the naltrexone group.
Participants who had their implants removed were included in the analysis using their last response carried forward. If these patients could not be contacted,would it not be a more conservative assumption thatthey would have relapsed?
The patient group who were living in controlled environments(prison or clinic),at follow up,were dealt with by using preadmission data. This group is missing from the flowchart. ... More
Conflict of interest: None Declared
Write a replyBack to top